Инсулин гларгин/Ликсисенатид (HOE901 / AVE0010)
Рандомизированное, 30-недельное активно контролируемое, открытое, с двумя рукавами и параллельными группами, многоцентровое исследование сравнения эффективности и безопасности фиксированной комбинации инсулин гларгин/ликсисенатид с инсулином гларгин с метформином или без метформина у пациентов с сахарным диабетом 2 типа
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/147/2014-03-27/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 230 чел. в стране «Россия».
- Центров в реестре: 13 в 8 городах. Список — ниже на странице.
- Плановая дата окончания (12.2015) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 12 · невключение: 24
Критерии включения
- Type 2 diabetes mellitus diagnosed at least 1 year before the screening visit.
- Treatment with basal insulin for at least 6 months before the screening visit.
- Stable basal insulin regimen (i.e. type of insulin and time/frequency of the injection) for at least 3 months before the screening visit.
- Stable (plus/minus 20 percent) total daily basal insulin dose between 15 and 40 Units/day for at least 2 months prior to the screening visit.
- For participants receiving basal insulin and 1 or 2 oral anti-diabetic drugs (OADs): the OAD dose(s) must be stable during the 3 months before the screening visit. The OADs could be 1 to 2 out of:
- metformin (more than or equal to 1500 mg/day or maximal tolerated dose),
- a sulfonylurea,
- a glinide,
- a dipeptidyl-peptidase-4 inhibitor,
- a sodium glucose co-transporter 2 inhibitor,
- Fasting Plasma Glucose (FPG) less than or equal to 180 mg/dL(10.0 mmol/L) at screening visit for participants receiving basal insulin in combination with 2 OADs or with 1 OAD other than metformin; FPG less than or equal to 200 mg/dL (11.1 mmol/L) at screening visit for participants on basal insulin only or basal insulin plus metformin at screening visit.
- Signed written informed consent.
Критерии невключения
- Age under legal age of adulthood at screening visit.
- HbA1c at screening visit less than 7.5% or above 10%.
- Pregnancy or lactation, women of childbearing potential with no effective contraceptive method.
- Use of other oral or injectable glucose-lowering agents than stated in the inclusion criteria in a period of 3 months prior to screening.
- Previous use of insulin other than basal insulin eg, prandial or pre-mixed insulin, in the year prior to screening. Note: Short term treatment (≤10 days) due to intercurrent illness is allowed.
- History discontinuation of a previous treatment with Glucagon Like Peptide -1 Receptor Agonists for safety/tolerability or lack of efficacy.
- Participant who had previously participated in any clinical trial with lixisenatide or the insulin glargine/lixisenatide FRC or had previously received lixisenatide.
- Use of weight loss drugs within 3 months prior to screening visit.
- Within the last 6 months prior to screening visit: history of stroke, myocardial infarction, unstable angina, or heart failure requiring hospitalization. Planned coronary, carotid or peripheral artery revascularisation procedures to be performed during the study period.
- History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy was already performed), chronic pancreatitis, pancreatitis during a previous treatment with incretin therapies, pancreatectomy, stomach/gastric surgery.
- Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes).
- Uncontrolled or inadequately controlled hypertension (systolic blood pressure above 180 mmHg or diastolic blood pressure above 95 mmHg) at screening visit.
- At screening visit, Body Mass Index (BMI) less than or equal to 20 or above 40 kg/m\^2.
- At screening visit amylase and/or lipase more than 3 times the upper limit of the normal (ULN) laboratory range.
- At screening visit alanine aminotransferase (ALT) or alkaline phosphatase (AST) more than 3 ULN.
- At screening visit calcitonin above or equal to 20 pg/mL (5.9 pmol/L).
- Any contraindication to metformin use, according to local labeling, if the participant was taking metformin.
- Participant who had a renal function impairment with creatinine clearance less than 30 mL/min (using the Cockcroft and Gault formula) or end-stage renal disease for participants, not treated with metformin.
- Exclusion criteria for randomization:
- HbA1c less than 7% or above 10% .
- Mean fasting SMPG calculated from the self-measurements for 7 days the week before randomization visit was above 140 mg/dL (7.8 mmol/L).
- Average insulin glargine daily dose less than 20 Units or above 50 Units (in the week before randomization visit).
- Amylase and/or lipase more than 3 ULN .
- The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Источник: ClinicalTrials.gov, NCT02058160 · запись обновлена в реестре 9 мая 2017.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 14
- Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30 — Baseline, Week 30
Цель исследования
Primary Objective:
To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 30.
Secondary Objective:
To compare the overall efficacy and safety of insulin glargine/lixisenatide FRC to insulin glargine (with or without metformin) over a 30 week treatment period in participants with type 2 diabetes.
Области и заболевания
Где проходит
13 центров в 8 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 147 от 27.03.2014 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик, центры
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02058160 Официальный реестр (США) · загружено 9 ноября 2026Цель
-
clinmarket · № 4567 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.